Cybrexa Therapeutics Announces First Patient Dosed with First-in-Class Peptide-Drug Conjugate CBX-12 in Phase 2 Trial in Ovarian Cancer
Primary target patient population for the CBX-12 Phase 2 study is women with platinum-resistant or refractory ovarian cancer who are naïve to ...
Cure Today7d
First Patient With Ovarian Cancer Receives Peptide-Drug Conjugate in Study
This trial is assessing CBX-12 as a potential treatment for ovarian cancer, with additional studies to be conducted in other ...
Eagle-Tribune9d
Cybrexa Therapeutics Announces First Patient Dosed with First-in-Class Peptide-Drug Conjugate ...
Oct. 07, 2024 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide-drug conjugate (PDC) therapeutics ...
Morningstar9d
Cybrexa Therapeutics Announces First Patient Dosed with First-in-Class Peptide-Drug Conjugate CBX-12 in Phase 2 Trial in Ovarian Cancer
Oct. 07, 2024 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide-drug conjugate (PDC) therapeutics ...
manilatimes9d
Cybrexa Therapeutics Announces First Patient Dosed with First-in-Class Peptide-Drug Conjugate CBX-12 in Phase 2 Trial in Ovarian Cancer
Register to read this story and more for free. Signing up for an account helps us improve your browsing experience.
Morningstar6d
Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs at 2024 EORTC-NCI-AACR Symposium
The first advance in the pre|CISION™ platform is the design and preclinical analysis of the Company’s newest development candidate, AVA6103, a novel, potent peptide drug conjugate (PDC ...